Veterinary Vaccine Market: By Animal Type (Sheep, Poultry, Pigs, Cattle and Companion Animal) By Vaccine Type (DNA Vaccines, Recombinant Vaccines, Conjugate Vaccines, and Companion Animal Vaccines, Others) Regional Analysis & Forecast - 2026
- OI-146 |
- Published date: Jul, 2019 |
- Animal Health |
- 120 Pages
Introduction
Animal Vaccine enhances the immunity of animals by improving animal health which avoids the transmission of diseases from animals to humans. These vaccines can be given subcutaneously or intramuscularly to the animal. The aim of veterinary vaccines is to improve livestock production in a cost-effective manner.
Market Overview
The Global Veterinary Vaccine Market was valued at $ 8.70 bn in 2018 and is forecasted to grow at a strong 5.4% CAGR between 2018 and 2026, resulting in 2026 global sales of $ 13.24. Market-driven by owing initiatives by animal associations, leading players and government agencies. However, a dearth of efficiency farm workers is hindering the market growth. Moreover, the growing incidence of zoonotic diseases is providing ample opportunities for the market.
Veterinary Vaccine depending on the type, companion animal vaccines segment is expected to account for the largest share of the Animal Vaccine market due to canine vaccines is the subsegment of companion animal vaccines. Whereas, the rapid proliferation of companion animal vaccines, advancement in diagnostic services and vaccine technology, and concerns over vaccine safety have contributed to the strong growth of the canine vaccine segment.
Key Developments
- 17-05-2019: HIPRA launched ICTHIOVAC® VNN, an injectable vaccine against Nodavirus for sea bass.
- 04-07-2019: At HIPRA they have launched to the market INMEVA®, the first inactivated vaccine against abortions caused by Chlamydia and Salmonella which reduces the appearance of clinical signs caused by both pathogens and also the shedding of these, helping to control the disease in the flock.
- 04-Jul-2019: HIPRA launches the vaccine HIPRADOG® 7 in Vietnam. They presented to the Vietnamese market their heptavalent vaccine for dogs against parvovirus, distemper, hepatitis, laryngotracheitis, and tracheobronchitis, and inactivated vaccine against canine leptospirosis.
Segmentation
The Global Veterinary Vaccine Market is segmented on the basis of Animal Type, Vaccine Type, and regions.
Based on the Animal Type: Sheep, Poultry, Pigs, Cattle, Companion animal.
Based on the Vaccine Type: DNA Vaccines, Recombinant Vaccines, Conjugate Vaccines, and Companion Animal Vaccines, Toxoid Vaccines, Subunit Vaccines, Livestock Vaccines, Inactivated Vaccines and Attenuated Vaccines.
Based on the Region: North America, Asia-Pacific, Europe, and LAMEA. Among that North America held the largest share of the market owing to the high adoption of companion animals, a rise in the consumption of meat and milk, and growing awareness regarding the benefits of using animal vaccines. Whereas, Asia-Pacific possesses a high market potential that could affect the animal vaccines market trends due to the increase in pet ownership and rise in the incidence of various zoonotic diseases
The key players of the Global Veterinary Vaccine market include Zoetis Inc., Virbac S.A, Vaxxinova Gmbh-Germany, Sanofi S.A., Romvac company S.A., Hygieia Biological Laboratories, Ceva Sant Animale, Boehringer Ingelheim GmbH, Anicon Labor GmbH, HIPRA, Phibro Animal Health Corp, Elanco, and Hester Biosciences Ltd.
Report Description: The report covers an in-depth analysis of the Global Veterinary Vaccine Market. The report assesses the market products pipeline by stage of development (early development, pre-clinical, clinical and in approval), By Animal Type (Sheep, Poultry, Pigs, Cattle and Companion animal). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.
The report includes in-depth company profiles of key players in the Global Animal Vaccine Market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments.
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Scope:
- Provides detailed analysis of the market structure along with forecast of the various segments and sub-segments of the Global Veterinary Vaccine Market
- Provides a comparative analysis of key marketed and pipeline products
- Provides key information on players involved in the Global Veterinary Vaccine Market
- Provides a complete overview of market segments and the regional outlook of Global Veterinary Vaccine Market
- Provides in-depth coverage of key news related to Global Veterinary Vaccine Market, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates
-
Data Collation (Primary & Secondary)
-
In-house Estimation (Based on proprietary databases and Models)
-
Market Triangulation
-
Forecasting
-
Market-related information is assembled from both primary and secondary sources.
-
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
-
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
-
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.
